{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T07:11:19Z","timestamp":1769152279413,"version":"3.49.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"11-12","license":[{"start":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T00:00:00Z","timestamp":1663113600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T00:00:00Z","timestamp":1663113600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81874123"],"award-info":[{"award-number":["81874123"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Apoptosis"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s10495-022-01769-2","type":"journal-article","created":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T15:02:56Z","timestamp":1663167776000},"page":"1004-1014","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Cuproptosis identifies respiratory subtype of renal cancer that confers favorable prognosis"],"prefix":"10.1007","volume":"27","author":[{"given":"Kunping","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linyi","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuqing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinfeng","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyi","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haowen","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenchen","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,14]]},"reference":[{"issue":"3","key":"1769_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209\u2013249","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"1769_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A (2020) Cancer statistics, 2020. CA Cancer J Clin 70(1):7\u201330","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"1769_CR3","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ctrv.2007.12.001","volume":"34","author":"K Gupta","year":"2008","unstructured":"Gupta K et al (2008) Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev 34(3):193\u2013205","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"1769_CR4","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.annonc.2020.11.016","volume":"32","author":"T Powles","year":"2021","unstructured":"Powles T, ESMO Guidelines Committee (2021) Recent eUpdate to the ESMO Clinical Practice Guidelines on renal cell carcinoma on cabozantinib and nivolumab for first-line clear cell renal cancer: Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 32(3):422\u2013423","journal-title":"Ann Oncol"},{"issue":"4","key":"1769_CR5","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41571-020-00455-z","volume":"18","author":"DA Braun","year":"2021","unstructured":"Braun DA et al (2021) Beyond conventional immune-checkpoint inhibition - novel immunotherapies for renal cell carcinoma. Nat Rev Clin Oncol 18(4):199\u2013214","journal-title":"Nat Rev Clin Oncol"},{"issue":"12","key":"1769_CR6","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/S0966-842X(99)01638-8","volume":"7","author":"S Labb\u00e9","year":"1999","unstructured":"Labb\u00e9 S, Thiele DJ (1999) Pipes and wiring: the regulation of copper uptake and distribution in yeast. Trends Microbiol 7(12):500\u2013505","journal-title":"Trends Microbiol"},{"issue":"5 Suppl","key":"1769_CR7","doi-asserted-by":"publisher","first-page":"1061S","DOI":"10.1093\/ajcn\/67.5.1061","volume":"67","author":"PJ Aggett","year":"1998","unstructured":"Aggett PJ, Fairweather-Tait S (1998) Adaptation to high and low copper intakes: its relevance to estimated safe and adequate daily dietary intakes. Am J Clin Nutr 67(5 Suppl):1061S-1063S","journal-title":"Am J Clin Nutr"},{"issue":"6586","key":"1769_CR8","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1126\/science.abf0529","volume":"375","author":"P Tsvetkov","year":"2022","unstructured":"Tsvetkov P et al (2022) Copper induces cell death by targeting lipoylated TCA cycle proteins. Science 375(6586):1254\u20131261","journal-title":"Science"},{"issue":"5","key":"1769_CR9","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/s41422-022-00653-7","volume":"32","author":"D Tang","year":"2022","unstructured":"Tang D, Chen X, Kroemer G (2022) Cuproptosis: a copper-triggered modality of mitochondrial cell death. Cell Res 32(5):417\u2013418","journal-title":"Cell Res"},{"issue":"9","key":"1769_CR10","doi-asserted-by":"publisher","first-page":"E866","DOI":"10.1073\/pnas.1319196111","volume":"111","author":"F Gatto","year":"2014","unstructured":"Gatto F, Nookaew I, Nielsen J (2014) Chromosome 3p loss of heterozygosity is associated with a unique metabolic network in clear cell renal carcinoma. Proc Natl Acad Sci USA 111(9):E866\u2013E875","journal-title":"Proc Natl Acad Sci USA"},{"key":"1769_CR11","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1186\/s12885-016-2688-0","volume":"16","author":"C Razafinjatovo","year":"2016","unstructured":"Razafinjatovo C et al (2016) Characterization of VHL missense mutations in sporadic clear cell renal cell carcinoma: hotspots, affected binding domains, functional impact on pVHL and therapeutic relevance. BMC Cancer 16:638","journal-title":"BMC Cancer"},{"issue":"11","key":"1769_CR12","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/nrc2502","volume":"8","author":"WG Kaelin Jr","year":"2008","unstructured":"Kaelin WG Jr (2008) The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer. Nat Rev Cancer 8(11):865\u2013873","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"1769_CR13","doi-asserted-by":"publisher","first-page":"3664","DOI":"10.1172\/JCI67230","volume":"123","author":"GL Semenza","year":"2013","unstructured":"Semenza GL (2013) HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. J Clin Invest 123(9):3664\u20133671","journal-title":"J Clin Invest"},{"issue":"1","key":"1769_CR14","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ccell.2015.12.004","volume":"29","author":"AA Hakimi","year":"2016","unstructured":"Hakimi AA et al (2016) An integrated metabolic atlas of clear cell renal cell carcinoma. Cancer Cell 29(1):104\u2013116","journal-title":"Cancer Cell"},{"issue":"3","key":"1769_CR15","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.tibs.2015.12.001","volume":"41","author":"MV Liberti","year":"2016","unstructured":"Liberti MV, Locasale JW (2016) The warburg effect: how does it benefit cancer cells? Trends Biochem Sci 41(3):211\u2013218","journal-title":"Trends Biochem Sci"},{"issue":"4","key":"1769_CR16","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1248\/bpb.b17-00992","volume":"41","author":"H Hatakeyama","year":"2018","unstructured":"Hatakeyama H et al (2018) Investigation of metabolomic changes in sunitinib-resistant human renal carcinoma 786-O cells by capillary electrophoresis-time of flight mass spectrometry. Biol Pharm Bull 41(4):619\u2013627","journal-title":"Biol Pharm Bull"},{"issue":"2","key":"1769_CR17","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1002\/ijc.32115","volume":"145","author":"T Sato","year":"2019","unstructured":"Sato T et al (2019) Value of global metabolomics in association with diagnosis and clinicopathological factors of renal cell carcinoma. Int J Cancer 145(2):484\u2013493","journal-title":"Int J Cancer"},{"key":"1769_CR18","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.148438","author":"H Nam","year":"2021","unstructured":"Nam H et al (2021) The TGF-beta\/HDAC7 axis suppresses TCA cycle metabolism in renal cancer. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.148438","journal-title":"JCI Insight"},{"issue":"1","key":"1769_CR19","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1038\/s41467-022-29577-x","volume":"13","author":"Y Qu","year":"2022","unstructured":"Qu Y et al (2022) A proteogenomic analysis of clear cell renal cell carcinoma in a Chinese population. Nat Commun 13(1):2052","journal-title":"Nat Commun"},{"key":"1769_CR20","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S Hanzelmann","year":"2013","unstructured":"Hanzelmann S, Castelo R, Guinney J (2013) GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics 14:7","journal-title":"BMC Bioinformatics"},{"issue":"43","key":"1769_CR21","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A et al (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102(43):15545\u201315550","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6084","key":"1769_CR22","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1126\/science.1218595","volume":"336","author":"M Jain","year":"2012","unstructured":"Jain M et al (2012) Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation. Science 336(6084):1040\u20131044","journal-title":"Science"},{"issue":"9","key":"1769_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0107468","volume":"9","author":"P Geeleher","year":"2014","unstructured":"Geeleher P, Cox N, Huang RS (2014) pRRophetic: an R package for prediction of clinical chemotherapeutic response from tumor gene expression levels. PLoS ONE 9(9):e107468","journal-title":"PLoS ONE"},{"key":"1769_CR24","doi-asserted-by":"publisher","DOI":"10.1126\/science.1260419","author":"M Uhl\u00e9n","year":"2015","unstructured":"Uhl\u00e9n M et al (2015) Tissue-based map of the human proteome. Science. https:\/\/doi.org\/10.1126\/science.1260419","journal-title":"Science"},{"key":"1769_CR25","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jproteome.8b00628","author":"J Liu","year":"2018","unstructured":"Liu J et al (2018) Loss of SETD2 induces a metabolic switch in renal cell carcinoma cell lines toward enhanced oxidative phosphorylation. J Proteome Res. https:\/\/doi.org\/10.1021\/acs.jproteome.8b00628","journal-title":"J Proteome Res"},{"issue":"3","key":"1769_CR26","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1074\/mcp.RA118.000957","volume":"18","author":"L Li","year":"2019","unstructured":"Li L et al (2019) Integrated genomic and proteomic analyses reveal novel mechanisms of the methyltransferase SETD2 in renal cell carcinoma development. Mol Cell Proteomics 18(3):437\u2013447","journal-title":"Mol Cell Proteomics"},{"key":"1769_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2022.03.006","author":"B Ljungberg","year":"2022","unstructured":"Ljungberg B et al (2022) European Association of Urology Guidelines on Renal Cell Carcinoma: the 2022 update. Eur Urol. https:\/\/doi.org\/10.1016\/j.eururo.2022.03.006","journal-title":"Eur Urol"},{"issue":"2","key":"1769_CR28","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.neo.2018.12.003","volume":"21","author":"AT Jones","year":"2019","unstructured":"Jones AT et al (2019) Efficacy of Dual inhibition of glycolysis and glutaminolysis for therapy of renal lesions in Tsc2+\/\u2212 mice. Neoplasia 21(2):230\u2013238","journal-title":"Neoplasia"},{"key":"1769_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.676142","volume":"9","author":"S Wang","year":"2021","unstructured":"Wang S et al (2021) Comprehensive analysis of ferroptosis regulators with regard to PD-L1 and immune infiltration in clear cell renal cell carcinoma. Front Cell Dev Biol 9:676142","journal-title":"Front Cell Dev Biol"},{"issue":"5","key":"1769_CR30","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","volume":"149","author":"SJ Dixon","year":"2012","unstructured":"Dixon SJ et al (2012) Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149(5):1060\u20131072","journal-title":"Cell"},{"key":"1769_CR31","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.canlet.2020.05.034","volume":"489","author":"ZA Bacigalupa","year":"2020","unstructured":"Bacigalupa ZA, Rathmell WK (2020) Beyond glycolysis: hypoxia signaling as a master regulator of alternative metabolic pathways and the implications in clear cell renal cell carcinoma. Cancer Lett 489:19\u201328","journal-title":"Cancer Lett"},{"key":"1769_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2022.05.029","author":"Y Xu","year":"2022","unstructured":"Xu Y et al (2022) Genomic profiling and response to immune checkpoint inhibition plus tyrosine kinase inhibition in FH-deficient renal cell carcinoma. Eur Urol. https:\/\/doi.org\/10.1016\/j.eururo.2022.05.029","journal-title":"Eur Urol"},{"issue":"7","key":"1769_CR33","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1177\/153537020222600712","volume":"226","author":"GJ Brewer","year":"2016","unstructured":"Brewer GJ (2016) Copper control as an antiangiogenic anticancer therapy: lessons from treating Wilson\u2019s disease. Exp Biol Med 226(7):665\u2013673","journal-title":"Exp Biol Med"},{"issue":"5","key":"1769_CR34","first-page":"1666","volume":"9","author":"BG Redman","year":"2003","unstructured":"Redman BG et al (2003) Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer. Clin Cancer Res 9(5):1666\u20131672","journal-title":"Clin Cancer Res"}],"container-title":["Apoptosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-022-01769-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10495-022-01769-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-022-01769-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T06:20:54Z","timestamp":1667024454000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10495-022-01769-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,14]]},"references-count":34,"journal-issue":{"issue":"11-12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1769"],"URL":"https:\/\/doi.org\/10.1007\/s10495-022-01769-2","relation":{},"ISSN":["1360-8185","1573-675X"],"issn-type":[{"value":"1360-8185","type":"print"},{"value":"1573-675X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,14]]},"assertion":[{"value":"23 August 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not available.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not available.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors read and approved the final manuscript.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}